肺表面活性物质治疗呼吸窘迫综合症疗效观察  

Observation of clinical efficacy of pulmonary surfactant in the treatment of acute respiratory distress syndrome

作　　者：朱筱珊[1] 刘光辉[1] 

机构地区：[1]安徽省立儿童医院新生儿科,安徽合肥230032

出　　处：《临床肺科杂志》2013年第10期1789-1791,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察肺表面活性物质(PS)在治疗足月儿和近足月儿呼吸窘迫综合症治疗中的作用;方法分析我院应用PS替代疗法救治患有呼吸窘迫综合症的足月和近足月新生儿21例的疗效;结果给予肺表面活性物质治疗后6 h、12 h、24 h两组患儿的氧合及通气功能(PaO2、PaCO2)明显改善(P<0.05),主要呼吸机参数(PIP、PEEP、FiO2)等指标均明显降低,21例患儿中19例有效,有效率90.4%,未见明显不良反应;结论肺表面活性物质替代治疗可以改善足月儿和近足月儿呼吸窘迫综合症的疗效,降低机械通气治疗时间,减少并发症。Objective To explore the clinical efficiency of the pulmonary surfactant replacement therapy for acute respiratory dis- tress syndrome （ARDS） in full-term and pre-term neonates. Methods The clinical efficacy of 21 full-term neonates who diagnosed with ARDS and were treated with PS were analyzed. Results After the pulmonary surfactant replacement therapy, the levels of PaO2 , PaCO2 and FiO2 were better improved in the treatment group than in the control group 6, 12, 24 hours after the treatment （ P 〈 0.05 ）. The main parameters of ventilation, including PIP, PEEP, and FiO2, decreased obviously after the treatment. The effective rate was 90.4% （ 19/ 21 ）. There was no significant adverse reaction occurred. Conclusion The application of pulmonary surfactant replacement treatment in full-term and pre-term infants with ARDS could improve their clinical efficiency and reduce the duration of ventilation and complications.

关 键 词：肺表面活性物质 足月儿 近足月儿 呼吸窘迫综合症 

分 类 号：R563.8[医药卫生—呼吸系统]